The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials
The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials
In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green's clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.Phil Reger and Cristina Green Will Serve as the Chief Information Officer and Vice President of Clinical Research, Respectively
菲尔·里格尔和克里斯蒂娜·格林将分别担任临床研究的首席信息官和副总裁
CERRITOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, is pleased to announce the hiring of two new executives. Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.
加利福尼亚州塞里托斯，2022年10月11日(环球通讯社)--美国最大的基于价值的肿瘤学组织之一肿瘤研究所，Inc.(纳斯达克：TOI)高兴地宣布招聘两名新高管。菲尔·里格尔将担任首席信息官，克里斯蒂娜·格林将担任临床研究副总裁。
As Chief Information Officer, a newly created position, Mr. Reger will lead enterprise-wide technology and data initiatives, developing strategies to support TOI's growth. Mr. Reger's professional experience includes 25 years of IT experience in high-growth environments, with 20 of them specializing in healthcare. Before joining TOI, Mr. Reger was part of the founding team that launched Radiology Partners, the largest radiology practice in the United States. As CTO, he launched and grew an IT department that met business demands for high levels of acquisitive growth, reliable clinical systems, and advanced capabilities. Most recently, he partnered with visionary clinicians and data scientists to develop an artificial intelligence platform enabling physicians to deliver industry-leading levels of patient care. Prior to Radiology Partners, he served as a key member of the DaVita IT leadership team.
作为首席信息官这一新设立的职位，雷杰先生将领导企业范围的技术和数据计划，制定支持TOI增长的战略。雷杰先生的专业经验包括在高增长环境中的25年IT经验，其中20年是医疗保健方面的专业经验。在加入TOI之前，雷杰先生是创办Radiology Partners的创始团队的一员，Radiology Partners是美国最大的放射学诊所。作为首席技术官，他创办并发展了一个IT部门，以满足企业对高水平的收购增长、可靠的临床系统和高级功能的需求。最近，他与富有远见的临床医生和数据科学家合作，开发了一个人工智能平台，使医生能够提供行业领先的患者护理水平。在加入Radiology Partners之前，他是DaVita IT领导团队的关键成员。
In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green's clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.
在担任临床研究部副总裁的新职务后，王志浩将负责TOI的临床研究部门，并扩大TOI患者参与临床试验的机会。格林女士拥有超过24年的临床研究经验，涉及多个不同领域，包括数据管理、项目管理、临床运营和职能领导。最近，她在Labcorp药物开发公司担任职务，带头开展临床试验的转型计划，包括移动医疗、分散临床试验和其他通过数据、技术和流程优化实现的研究设计创新。在2015年至2017年担任董事拉丁美洲首席执行官和2011年至2015年担任北美区首席执行官期间，格林女士还领导了多个国家的大型临床运营团队。
TOI's CEO Brad Hively commented, "TOI thrives on incredible leadership, and I couldn't be more excited about these two seasoned leaders joining our team. The roles that Phil and Cristina fill are especially vital as we enhance our focus on research, technology, and health equity. I am confident that their contributions will help us advance even further."
TOI的首席执行官布拉德·海弗利评论说：“TOI依靠令人难以置信的领导力而蓬勃发展，我对这两位经验丰富的领导者加入我们的团队感到无比兴奋。在我们加强对研究、技术和医疗公平的关注之际，菲尔和克里斯蒂娜所扮演的角色尤为重要。我相信他们的贡献将帮助我们进一步发展。”
About The Oncology Institute
关于肿瘤学研究所
Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.6 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in more than 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .
成立于2007年的希望与创新肿瘤学研究所(TOI)通过在社区环境中提供高度专业化的、基于价值的癌症护理来推动肿瘤学的发展。TOI为大约160万名患者提供基于证据的尖端癌症护理，包括临床试验、输血和其他传统上与最先进的医疗机构相关的护理提供模式。拥有80多名受雇的临床医生和500多名队友，分布在50多个诊所，而且还在不断增长，TOI正在让肿瘤学变得更好。有关更多信息，请访问。
Contacts
联系人
Media
The Oncology Institute
Julie Korinke
JulieKorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
媒体
肿瘤学研究所
朱莉·科林克
邮箱：JulieKorinke@theoncologyInstitute te.com
(562) 735-3226 x 88806
Juan Lezama
juanlezama@theoncologyinstitute.com(562) 374-8434
胡安·莱扎马
邮箱：juanlezama@theoncologyInstitute te.com(562)374-8434
Investors
Solebury Trout
Maria Lycouris
mlycouris@soleburytrout.com
投资者
索尔伯里鲑鱼
玛丽亚·吕库利斯
邮箱：mlyCouris@soleburyrout.com